Ligands for Ser/Thr phosphoprotein phosphatases: a patent review (2005-2015)

References

• Shi Y. Serine/threonine phosphatases: Mechanism through structure. Cell. 2009;139:468–484.
   PubMed Web of Science ®Google Scholar
• Zhang M, Yogesha SD, Mayfield JE, et al. Viewing serine/threonine protein phosphatases through the eyes of drug designers. Febs J. 2013;280:4739–4760.
   PubMed Web of Science ®Google Scholar
• Cohen P. Protein kinases–the major drug targets of the twenty-first century? Nat Rev Drug Discov. 2002;1:309–315.
   PubMed Web of Science ®Google Scholar
• McConnell JL, Wadzinski BE. Targeting protein serine/threonine phosphatases for drug development. Mol Pharmacol. 2009;75:1249–1261.
   PubMed Web of Science ®Google Scholar
• Oliver CJ, Shenolikar S. Physiologic importance of protein phosphatase inhibitors. Front Biosci. 1998;3:D961–D972.
   PubMedGoogle Scholar
• Egloff MP, Cohen PT, Reinemer P, et al. Crystal structure of the catalytic subunit of human protein phosphatase 1 and its complex with tungstate. J Mol Biol. 1995;254:942–959.
   PubMed Web of Science ®Google Scholar
• Goldberg J, Huang HB, Kwon YG, et al. Three-dimensional structure of the catalytic subunit of protein serine/threonine phosphatase-1. Nature. 1995;376:745–753.
   PubMed Web of Science ®Google Scholar
• Swingle MR, Amable L, Lawhorn BG, et al. Structure-activity relationship studies of fostriecin, cytostatin, and key analogs, with PP1, PP2A, PP5, and(beta12-beta13)-chimeras (PP1/PP2a and PP5/PP2A), provide further insight into the inhibitory actions of fostriecin family inhibitors. J Pharmacol Exp Ther. 2009;331:45–53.
   PubMed Web of Science ®Google Scholar
• Swingle M, Ni L, Honkanen RE. Small-molecule inhibitors of ser/thr protein phosphatases: specificity, use and common forms of abuse. Methods Mol Biol. 2007;365:23–38.
   PubMedGoogle Scholar
• The Trustees of the University of Princeton. Modulators of protein phosphatase 2A holoenzyme. WO127387; 2008.
   Google Scholar
• The Trustees of the University of Princeton. Modulators of protein phosphatase 2A holoenzyme. WO060791; 2008.
   Google Scholar
• Liu J, Farmer JD Jr., Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporin a and fkbp-fk506 complexes. Cell. 1991;66:807–815.
   PubMed Web of Science ®Google Scholar
• Matsuoka Y, Nagahara Y, Ikekita M, et al. A novel immunosuppressive agent FTY720 induced akt dephosphorylation in leukemia cells. Br J Pharmacol. 2003;138:1303–1312.
   PubMed Web of Science ®Google Scholar
• Voronkov M, Braithwaite SP, Stock JB. Phosphoprotein phosphatase 2a: A novel druggable target for alzheimer’s disease. Future Med Chem. 2011;3:821–833.
   PubMed Web of Science ®Google Scholar
• Ceulemans H, Bollen M. Functional diversity of protein phosphatase-1, a cellular economizer and reset button. Physiol Rev. 2004;84:1–39.
   PubMed Web of Science ®Google Scholar
• Board of Trustees of the University of Illinois. Composition and method for preventing or treating a taupathy. US0142602; 2012.
   Google Scholar
• Garcia A, Cayla X, Caudron B, et al. New insights in protein phosphorylation: A signature for protein phosphatase 1 interacting proteins. C R Biol. 2004;327:93–97.
   PubMed Web of Science ®Google Scholar
• Chatterjee J, Beullens M, Sukackaite R, et al. Development of a peptide that selectively activates protein phosphatase-1 in living cells. Angew Chem Int Ed Engl. 2012;51:10054–10059.
   PubMed Web of Science ®Google Scholar
• European Molecular Biology Laboratory. A cell-permeable and selective activator of protein phosphatase-1. WO124425; 2013.
   Google Scholar
• Bharucha DC, Zhou M, Nekhai S, et al. A protein phosphatase from human t cells augments tat transactivation of the human immunodeficiency virus type 1 long-terminal repeat. Virology. 2002;296:6–16.
   PubMed Web of Science ®Google Scholar
• Ammosova T, Yedavalli VR, Niu X, et al. Expression of a protein phosphatase 1 inhibitor, cdnipp1, increases cdk9 threonine 186 phosphorylation and inhibits hiv-1 transcription. J Biol Chem. 2011;286:3798–3804.
   PubMed Web of Science ®Google Scholar
• Howard University. Inhibitors of protein phosphatase-1 and uses thereof. WO129224; 2009.
   Google Scholar
• Ilinykh PA, Tigabu B, Ivanov A, et al. Role of protein phosphatase 1 in dephosphorylation of ebola virus vp30 protein and its targeting for the inhibition of viral transcription. J Biol Chem. 2014;289:22723–22738.
   PubMed Web of Science ®Google Scholar
• Howard University. Inhibitors of protein phosphatase-1 and used thereof. WO028051; 2014.
   Google Scholar
• Xia D, Stull JT, Kamm KE. Myosin phosphatase targeting subunit 1 affects cell migration by regulating myosin phosphorylation and actin assembly. Exp Cell Res. 2005;304:506–517.
   PubMed Web of Science ®Google Scholar
• Georgetown University. Myosin light chain phosphatase inhibitors. WO146013; 2009.
   Google Scholar
• Grindrod S, Suy S, Fallen S, et al. Effects of a fluorescent myosin light chain phosphatase inhibitor on prostate cancer cells. Front Oncol. 2011;1:27.
   PubMedGoogle Scholar
• Intrexon Corporation. PP1 ligands. WO137681; 2008.
   Google Scholar
• Gwangju Institute of Science and Technology. Decoy peptides inhibiting protein phosphatase 1-mediated dephosphorylation of phospholamban. WO007584; 2014.
   Google Scholar
• Boyce M, Bryant KF, Jousse C, et al. A selective inhibitor of eif2alpha dephosphorylation protects cells from er stress. Science. 2005;307:935–939.
   PubMed Web of Science ®Google Scholar
• Tsaytler P, Harding HP, Ron D, et al. Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science. 2011;332:91–94.
   PubMed Web of Science ®Google Scholar
• Pierre P, INSERM. Inhibitors of the PP1/GADD34 complex for the treatment of a condition requiring an immunosuppresive activity. US0126549; 2015.
   Google Scholar
• Universität Dortmund. Decaline-derived compounds as pharmaceutically active agents. WO069787; 2006.
   Google Scholar
• Scheck M, Koch MA, Waldmann H. Synthesis of a dysidiolide-inspired compound library and discovery of acetylcholinesterase inhibitors based on protein structure similarity clustering (pssc). Tetrahedron. 2008;64:4792–4802.
   Web of Science ®Google Scholar
• Xing Y, Xu Y, Chen Y, et al. Structure of protein phosphatase 2A core enzyme bound to tumor-inducing toxins. Cell. 2006;127:341–353.
   PubMed Web of Science ®Google Scholar
• Haesen D, Sents W, Lemaire K, et al. The basic biology of PP2A in hematologic cells and malignancies. Front Oncol. 2014;4:347.
   PubMedGoogle Scholar
• Ruediger R, Pham HT, Walter G. Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the a alpha subunit gene. Oncogene. 2001;20:10–15.
   PubMed Web of Science ®Google Scholar
• Ruediger R, Pham HT, Walter G. Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the a beta subunit gene. Oncogene. 2001;20:1892–1899.
   PubMed Web of Science ®Google Scholar
• McConechy MK, Anglesio MS, Kalloger SE, et al. Subtype-specific mutation of PPP2r1a in endometrial and ovarian carcinomas. J Pathol. 2011;223:567–573.
   PubMed Web of Science ®Google Scholar
• Chou H-C, Chen C-H, Lee H-S, et al. Alterations of tumour suppressor gene PPP2r1b in hepatocellular carcinoma. Cancer Lett. 2007;253:138–143.
   PubMed Web of Science ®Google Scholar
• Cristobal I, Manso R, Rincon R, et al. PP2aA inhibition is a common event in colorectal cancer and its restoration using fty720 shows promising therapeutic potential. Mol Cancer Ther. 2014;13:938–947.
   PubMed Web of Science ®Google Scholar
• Cristobal I, Garcia-Orti L, Cirauqui C, et al. Overexpression of set is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica. 2012;97:543–550.
   PubMed Web of Science ®Google Scholar
• Chen LP, Lai YD, Li DC, et al. Alpha4 is highly expressed in carcinogen-transformed human cells and primary human cancers. Oncogene. 2011;30:2943–2953.
   PubMed Web of Science ®Google Scholar
• Puustinen P, Junttila MR, Vanhatupa S, et al. PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2a-mediated inactivation in human malignant glioma. Cancer Res. 2009;69:2870–2877.
   PubMed Web of Science ®Google Scholar
• Wandzioch E, Pusey M, Werda A, et al. PME-1 modulates protein phosphatase 2A activity to promote the malignant phenotype of endometrial cancer cells. Cancer Res. 2014;74:4295–4305.
   PubMed Web of Science ®Google Scholar
• Li W, Xie L, Chen Z, et al. Cantharidin, a potent and selective PP2A inhibitor, induces an oxidative stress-independent growth inhibition of pancreatic cancer cells through g2/m cell-cycle arrest and apoptosis. Cancer Sci. 2010;101:1226–1233.
   PubMed Web of Science ®Google Scholar
• Duong FH, Dill MT, Matter MS, et al. Protein phosphatase 2A promotes hepatocellular carcinogenesis in the diethylnitrosamine mouse model through inhibition of p53. Carcinogenesis. 2014;35:114–122.
   PubMed Web of Science ®Google Scholar
• Lu J, Kovach JS, Johnson F, et al. Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proc Natl Acad Sci U S A. 2009;106:11697–11702.
   PubMed Web of Science ®Google Scholar
• Boudreau RT, Conrad DM, Hoskin DW. Apoptosis induced by protein phosphatase 2a (PP2A) inhibition in t leukemia cells is negatively regulated by PP2A-associated p38 mitogen-activated protein kinase. Cell Signal. 2007;19:139–151.
   PubMed Web of Science ®Google Scholar
• Liu F, Grundke-Iqbal I, Iqbal K, et al. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci. 2005;22:1942–1950.
   PubMed Web of Science ®Google Scholar
• Torrent L, Ferrer I. PP2A and alzheimer disease. Curr Alzheimer Res. 2012;9:248–256.
   PubMed Web of Science ®Google Scholar
• Sontag E, Nunbhakdi-Craig V, Lee G, et al. Regulation of the phosphorylation state and microtubule-binding activity of tau by protein phosphatase 2A. Neuron. 1996;17:1201–1207.
   PubMed Web of Science ®Google Scholar
• Jerecic J, Williams J, Bucaria J, et al. Interaction of NMDA receptor with protein serine threonine phosphatases. US0074831; 2005.
   Google Scholar
• Braithwaite SP, Stock JB, Mouradian MM. α-Synuclein phosphorylation as a therapeutic target in Parkinson’s disease. Rev Neurosci. 2012;23:191–198.
   PubMed Web of Science ®Google Scholar
• Gutierrez A, Pan L, Groen RW, et al. Phenothiazines induce PP2A-mediated apoptosis in t cell acute lymphoblastic leukemia. J Clin Invest. 2014;124:644–655.
   PubMed Web of Science ®Google Scholar
• De Los Rios C, Egea J, Marco-Contelles J, et al. Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives. J Med Chem. 2010;53:5129–5143.
   PubMed Web of Science ®Google Scholar
• Lorrio S, Romero A, Gonzalez-Lafuente L, et al. PP2A ligand ITH12246 protects against memory impairment and focal cerebral ischemia in mice. ACS Chem Neurosci. 2013;4:1267–1277.
   PubMed Web of Science ®Google Scholar
• Velacor Therapeutics PTY LTD. Methods and compositions for the treatment of phosphatase-related disorders. WO043116; 2009.
   Google Scholar
• Velacor Therapeutics Pty Ltd. Treatment of neurodegenerative diseases. US0141104; 2014.
   Google Scholar
• Hovens C, Corcoran N. Treatment of neurodegenerative diseases. WO109851; 2007.
   Google Scholar
• Velacor Therapeutics Pty Ltd. Treatment of neurological disorders. WO119109; 2008.
   Google Scholar
• Velacor Therapeutic Pty Ltd. Treatment of neurological disorders. US0140130; 2015.
   Google Scholar
• Dobrowsky RT, Kamibayashi C, Mumby MC, et al. Ceramide activates heterotrimeric protein phosphatase 2A. J Biol Chem. 1993;268:15523–15530.
   PubMed Web of Science ®Google Scholar
• Chohan MO, Khatoon S, Iqbal I-G, et al. Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by memantine. FEBS Lett. 2006;580:3973–3979.
   PubMed Web of Science ®Google Scholar
• Chen C-L, Lin C-F, Chiang C-W, et al. Lithium inhibits ceramide- and etoposide-induced protein phosphatase 2A methylation, Bcl-2 dephosphorylation, caspase-2 activation, and apoptosis. Mol Pharmacol. 2006;70:510–517.
   PubMed Web of Science ®Google Scholar
• Chalfant CE, Kishikawa K, Mumby MC, et al. Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid. J Biol Chem. 1999;274:20313–20317.
   PubMed Web of Science ®Google Scholar
• Chalfant CE, Szulc Z, Roddy P, et al. The structural requirements for ceramide activation of serine-threonine protein phosphatases. J Lipid Res. 2004;45:496–506.
   PubMed Web of Science ®Google Scholar
• Christensen DJ, Ohkubo N, Oddo J, et al. Apolipoprotein e and peptide mimetics modulate inflammation by binding the set protein and activating protein phosphatase 2a. J Immunol. 2011;186:2535–2542.
   PubMed Web of Science ®Google Scholar
• Switzer CH, Cheng RY, Vitek TM, et al. Targeting set/i(2)PP2a oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene. 2011;30:2504–2513.
   PubMed Web of Science ®Google Scholar
• Vitek MP, Christensen DJ, Wilcock D, et al. APOE-mimetic peptides reduce behavioral deficits, plaques and tangles in alzheimer’s disease transgenics. Neurodegener Dis. 2012;10:122–126.
   PubMed Web of Science ®Google Scholar
• Feschenko MS, Stevenson E, Nairn AC, et al. A novel camp-stimulated pathway in protein phosphatase 2A activation. J Pharmacol Exp Ther. 2002;302:111–118.
   PubMed Web of Science ®Google Scholar
• Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis cml through the inhibitory activity of the bcr/abl-regulated set protein. Cancer Cell. 2005;8:355–368.
   PubMed Web of Science ®Google Scholar
• Signum Biosciences. Compositions and methods for enhancing cognitive function. WO084033 (2006)
   Google Scholar
• Vafai S, Voronkov M, Stock M, et al. Compound, compositions and methods for making the same. US0264496; 2009.
   Google Scholar
• Lee KW, Chen W, Junn E, et al. Enhanced phosphatase activity attenuates alpha-synucleinopathy in a mouse model. J Neurosci. 2011;31:6963–6971.
   PubMed Web of Science ®Google Scholar
• Lee K-W, Im J-Y, Woo J-M, et al. Neuroprotective and anti-inflammatory properties of a coffee component in the mptp model of parkinson’s disease. Neurotherapeutics. 2013;10:143–153.
   PubMed Web of Science ®Google Scholar
• Basurto-Islas G, Blanchard J, Tung YC, et al. Therapeutic benefits of a component of coffee in a rat model of alzheimer’s disease. Neurobiol Aging. 2014;35:2701–2712.
   PubMed Web of Science ®Google Scholar
• The. Trustees of Princeton University. Modulators of protein phosphatase 2A and PP2A methyl esterase. US0239244; 2009.
   Google Scholar
• Rossman IT, Cohen JA. Multiple sclerosis: Switching sides–fingolimod versus injectable ms therapies. Nat Rev Neurol. 2015;11:316–317.
   PubMed Web of Science ®Google Scholar
• Neviani P, Santhanam R, Oaks JJ, et al. Fty720, a new alternative for treating blast crisis chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest. 2007;117:2408–2421.
   PubMed Web of Science ®Google Scholar
• Lim KG, Sun C, Bittman R, et al. (R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: Effect on sphingosine kinase 2 expression in HEK293 cells and actin rearrangement and survival of MCF-7 breast cancer cells. Cell Signal. 2011;23:1590–1595.
   PubMed Web of Science ®Google Scholar
• Omar HA, Chou -C-C, Berman-Booty LD, et al. Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology. 2011;53:1943–1958.
   PubMed Web of Science ®Google Scholar
• The Ohio State University Research Foundation. Inhibition of leukemic stem cells by PP2A activating agents. WO181488; 2013.
   Google Scholar
• Ohio State Innovation Foundation. Inhibition of leukemic stem cells by PP2A activating agents. US0141502; 2015.
   Google Scholar
• Shaikh RS, Schilson SS, Wagner S, et al. Synthesis and evaluation of fluorinated fingolimod (FTY720) analogues for sphingosine-1-phosphate receptor molecular imaging by positron emission tomography. J Med Chem. 2015;58:3471–3484.
   PubMed Web of Science ®Google Scholar
• The Regents of the University of California. Azacyclic constrained analogs of FTY720. WO009731; 2015.
   Google Scholar
• Schweiger S, Schneider R, Glossman H. Treatment of Alzheimer’s disease. US0184624; 2012
   Google Scholar
• Lixte Biotechnology, Inc. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase. WO014141; 2014.
   Google Scholar
• Lixte Biotecnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury. WO005080; 2014.
   Google Scholar
• Weinbrenner C, Baines CP, Liu GS, et al. Fostriecin, an inhibitor of protein phosphatase 2A, limits myocardial infarct size even when administered after onset of ischemia. Circulation. 1998;98:899–905.
   PubMed Web of Science ®Google Scholar
• Barancik M, Htun P, Schaper W. Okadaic acid and anisomycin are protective and stimulate the sapk/jnk pathway. J Cardiovasc Pharmacol. 1999;34:182–190.
   PubMed Web of Science ®Google Scholar
• Matsui T, Tao J, Del Monte F, et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation. 2001;104:330–335.
   PubMed Web of Science ®Google Scholar
• Galbo T, Olsen GS, Quistorff B, et al. Free fatty acid-induced PP2A hyperactivity selectively impairs hepatic insulin action on glucose metabolism. PLoS One. 2011;6:e27424.
   PubMed Web of Science ®Google Scholar
• Kowluru A, Matti A. Hyperactivation of protein phosphatase 2A in models of glucolipotoxicity and diabetes: Potential mechanisms and functional consequences. Biochem Pharmacol. 2012;84:591–597.
   PubMed Web of Science ®Google Scholar
• Lixte Biotecnnology. Oxabycyloheptanes and oxabicycloheptenes for the treatment of diabetes. WO005084; 2014.
   Google Scholar
• Lixte Biotechnology, Inc. Formulations of oxabicyclopheptanes and oxabicyloheptenes. WO168941; 2014.
   Google Scholar
• Lixte Biotechnology. Protein phosphatase inhibitors that cross the blood brain barrier. WO073802; 2015.
   Google Scholar
• The University of Newcastle Research Associates. Anhydride modified cantharidin analogues useful in the treatment of cancer. US0110822; 2004.
   Google Scholar
• Tarleton M, Gilbert J, Sakoff JA, et al. Synthesis and anticancer activity of a series of norcantharidin analogues. Eur J Med Chem. 2012;54:573–581.
   PubMed Web of Science ®Google Scholar
• Thaqi A, Scott JL, Gilbert J, et al. Synthesis and biological activity of delta-5,6-norcantharimides: Importance of the 5,6-bridge. Eur J Med Chem. 2010;45:1717–1723.
   PubMed Web of Science ®Google Scholar
• Hill TA, Stewart SG, Gordon CP, et al. Norcantharidin analogues: Synthesis, anticancer activity and protein phosphatase 1 and 2A inhibition. ChemMedChem. 2008;3:1878–1892.
   PubMed Web of Science ®Google Scholar
• Hill TA, Stewart SG, Sauer B, et al. Heterocyclic substituted cantharidin and norcantharidin analogues–synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity. Bioorg Med Chem Lett. 2007;17:3392–3397.
   PubMed Web of Science ®Google Scholar
• Endo S, Suzuki M, Sumi M, et al. Molecular identification of human g-substrate, a possible downstream component of the cgmp-dependent protein kinase cascade in cerebellar purkinje cells. Proc Natl Acad Sci U S A. 1999;96:2467–2472.
   PubMed Web of Science ®Google Scholar
• The McClean Hospital Corporation. G-substrate for the treatment and prevention of parkinson’s disease. WO112701 (2008)
   Google Scholar
• Rusnak F, Mertz P. Calcineurin: Form and function. Physiol Rev. 2000;80:1483–1521.
   PubMed Web of Science ®Google Scholar
• Ecole Normale Superieure de Lyon and Centro National de la Recherche Scientifique. Polypeptides having modulatory effects on cells. US0245092; 2012.
   Google Scholar
• Aramburu J, Garcia-Cozar F, Raghavan A, et al. Selective inhibition of nfat activation by a peptide spanning the calcineurin targeting site of nfat. Mol Cell. 1998;1:627–637.
   PubMed Web of Science ®Google Scholar
• Garcia-Cozar FJ, Okamura H, Aramburu JF, et al. Two-site interaction of nuclear factor of activated t cells with activated calcineurin. J Biol Chem. 1998;273:23877–23883.
   PubMed Web of Science ®Google Scholar
• Jain J, McCaffrey PG, Miner Z, et al. The T-cell transcription factor nfatp is a substrate for calcineurin and interacts with fos and jun. Nature. 1993;365:352–355.
   PubMed Web of Science ®Google Scholar
• Crabtree GR, Clipstone NA. Signal transmission between the plasma membrane and nucleus of T lymphocytes. Annu Rev Biochem. 1994;63:1045–1083.
   PubMed Web of Science ®Google Scholar
• Huai Q, Kim H-Y, Liu Y, et al. Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes. Proc Natl Acad Sci U S A. 2002;99:12037–12042.
   PubMed Web of Science ®Google Scholar
• Griffith JP, Kim JL, Kim EE, et al. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant fkbp12-fk506 complex. Cell. 1995;82:507–522.
   PubMed Web of Science ®Google Scholar
• Roehrl MH, Kang S, Aramburu J, et al. Selective inhibition of calcineurin-nfat signaling by blocking protein-protein interaction with small organic molecules. Proc Natl Acad Sci U S A. 2004;101:7554–7559.
   PubMed Web of Science ®Google Scholar
• Musson RE, Smit NP. Regulatory mechanisms of calcineurin phosphatase activity. Curr Med Chem. 2011;18:301–315.
   PubMed Web of Science ®Google Scholar
• Ewha University. Novel tacrolimus derivatives, a neuroprotective composition comprising the same, an immunosuppressive composition comprising the same, a method for preparing the same, and a mutant for producing the same. WO026665; 2012.
   Google Scholar
• Consejo Superior de Investigaciones Científicas. Peptides, nucleotide sequences and cnalinker13 cells and applications thereof. WO064072; 2006.
   Google Scholar
• Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III. Method to screen for selective peptides that inhibit the biological activity of calcinerin. US0296482; 2014.
   Google Scholar
• Inserm Calcineurin inhibitors for use in the treatment of lesional vestibular disorders. WO124416; 2013.
   Google Scholar
• Lu ZR, Gao SQ, Kopeckova P, et al. Synthesis of bioadhesive lectin-hpma copolymer-cyclosporin conjugates. Bioconjug Chem. 2000;11:3–7.
   PubMed Web of Science ®Google Scholar
• Allergan. Cyclosporin analogs. WO051193; 2012.
   Google Scholar
• Allergan. Cyclosporin analogs. US0065433; 2015.
   Google Scholar
• Hinds TD Jr., Sanchez ER. Protein phosphatase 5. Int J Biochem Cell Biol. 2008;40:2358–2362.
   PubMed Web of Science ®Google Scholar
• Chen MX, McPartlin AE, Brown L, et al. A novel human protein serine/threonine phosphatase, which possesses four tetratricopeptide repeat motifs and localizes to the nucleus. Embo J. 1994;13:4278–4290.
   PubMed Web of Science ®Google Scholar
• Kang H, Sayner SL, Gross KL, et al. Identification of amino acids in the tetratricopeptide repeat and c-terminal domains of protein phosphatase 5 involved in autoinhibition and lipid activation. Biochemistry. 2001;40:10485–10490.
   PubMed Web of Science ®Google Scholar
• Chen MS, Silverstein AM, Pratt WB, et al. The tetratricopeptide repeat domain of protein phosphatase 5 mediates binding to glucocorticoid receptor heterocomplexes and acts as a dominant negative mutant. J Biol Chem. 1996;271:32315–32320.
   PubMed Web of Science ®Google Scholar
• Urban G, Golden T, Aragon IV, et al. Identification of an estrogen-inducible phosphatase (PP5) that converts MCF-7 human breast carcinoma cells into an estrogen-independent phenotype when expressed constitutively. J Biol Chem. 2001;276:27638–27646.
   PubMed Web of Science ®Google Scholar
• Yang J, Roe SM, Cliff MJ, et al. Molecular basis for tpr domain-mediated regulation of protein phosphatase 5. Embo J. 2005;24:1–10.
   PubMed Web of Science ®Google Scholar
• Chinkers M. Protein phosphatase 5 in signal transduction. Trends Endocrinol Metab. 2001;12:28–32.
   PubMed Web of Science ®Google Scholar
• Bahl R, Bradley KC, Thompson KJ, et al. Localization of protein ser/thr phosphatase 5 in rat brain. Brain Res Mol Brain Res. 2001;90:101–109.
   PubMedGoogle Scholar
• Deutsches Zentrum für Neurodegenerative Erkrankungen. Activators of protein phosphatase 5. EP2878677; 2015.
   Google Scholar
• Brautigan DL. Protein ser/thr phosphatases–the ugly ducklings of cell signalling. Febs J. 2013;280:324–345.
   PubMed Web of Science ®Google Scholar
• De Munter S, Kohn M, Bollen M. Challenges and opportunities in the development of protein phosphatase-directed therapeutics. ACS Chem Biol. 2013;8:36–45.
   PubMed Web of Science ®Google Scholar